In Jurkat T cell activation experiments, significant CD69 upregulation occurred only when the T cell line was co-cultured with HeLa (EGFR+) tumor cells in the presence of EGFR-LiTE-transfected cell supernatant, but not when co-cultured with NALM6 (EGFR-) cells or in the presence of mock-transfected cell supernatant (Figures 1G, H), suggesting that the secreted TCE specifically mediates T cell activation against EGFR-positive tumor cells. The gene discussed is CD69; the disease is neoplasm.